Timothy Chan, M.D., Ph.D., chair of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic (IMAGE)

Cleveland Clinic

Timothy Chan, M.D., Ph.D., chair of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic

Caption

New research led by Dr. Timothy Chan of Cleveland Clinic is demonstrating that pathogenic polymerase epsilon and delta (POLE/POLD1) genetic mutations lead to improved response to immune checkpoint blockade, a powerful class of immunotherapy drugs.

Credit

Cleveland Clinic

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.